TABLE 3.
β-Lactam susceptibilities of E. coli DH5α(pBC-CMY16) producing the CMY-16 enzyme and DH5α(pBC-SK)
| Antibiotica | MIC (μg/ml)
|
|
|---|---|---|
| DH5α(pBC-CMY16) | DH5α(pBC-SK) | |
| Ampicillin | >128 | 1 |
| Amoxicillin/clavulanate | 32 | 1 |
| Piperacillin | 64 | 0.5 |
| Piperacillin/tazobactam | 2 | 0.5 |
| Cephalothin | >128 | 2 |
| Cefotaxime | 32 | 0.02 |
| Ceftriaxone | 32 | 0.02 |
| Ceftazidime | 32 | 0.12 |
| Cefepime | 0.25 | 0.02 |
| Aztreonam | 16 | 0.02 |
| Imipenem | 0.12 | 0.09 |
| Meropenem | 0.02 | 0.01 |
| Cefoxitin | 32 | 2 |
a
Amoxicillin/clavulanate at a 2:1 ratio; tazobactam fixed concentration of 4 μg/ml.